Essential AD2 Clinical ResearchEssential AD2 has been clinically proven to reduce acetaldehyde and improve liver health in those with ALDH2 Deficiency.
Decrease in Blood Acetaldehyde in Those With ALDH2 Deficiency After Taking Essential AD2 for 28 Days
Clinical Results: Essential AD2 reduces the build-up of acetaldehyde up to 49% after 20 minutes following alcohol consumption.
Improvement in Liver Function Tests in Those with ALDH2 Deficiency After Taking Essential AD2 for 28 Days
Clinical Results: Essential AD2 Improves Liver Function Tests, decreasing AST and ALT. When high, AST and ALT are indicators of liver damage or injury.
Below is the abstract of the clinical research conducted on Essential AD2 in those with ALDH2 Deficiency. The research was performed by an independent third-party clinical research organization. Clinical data demonstrated significant reductions in blood acetaldehyde levels in individuals with ALDH2 Deficiency.
The research also demonstrated decreases in liver enzymes that are used as indicators of liver damage and disease. AST and ALT together are called the Liver Function Test. These enzymes typically increase if there is liver damage. The two figures on this page show the results of this research.
Although there are many sources of acetaldehyde, alcohol was used as the source of acetaldehyde for this research due to ease of administration. The full report has been submitted to the American Journal of Therapeutics and will be published soon.
Introduction: It is estimated that 1 billion people in the world have a point mutation in the gene encoding the Aldehyde Dehydrogenase 2 (ALDH2) enzyme, the primary enzyme responsible for the metabolism of acetaldehyde. The presence of this mutation is called ALDH2 Deficiency. Due to limited ability to metabolize acetaldehyde, individuals with ALDH2 Deficiency experience elevated levels of blood acetaldehyde following exposure to various common sources such as recreational alcohol. Due to higher levels of acetaldehyde, individuals with ALDH2 Deficiency are at higher risk for numerous diseases, including liver cirrhosis, esophageal and gastric cancer, osteoporosis, and Alzheimer’s disease.
Objectives & Outcome Measures: The present trial was designed to study the effectiveness, safety, and tolerability of a nutritional supplement (Essential AD2). The primary outcome was change in acetaldehyde levels in the blood following exposure to alcohol in individuals with ALDH2 Deficiency before and after use of study nutritional supplement.
Design: This was a 28 day open label trial, comparing initial acetaldehyde levels after alcohol ingestion to levels after 28 days of a nutritional supplement (Essential AD2).
Subjects: Subjects were genotyped to be heterozygous for the ALDH2 gene mutation.
Interventions & Results: ALDH2 Deficient subjects showed a decrease in average blood acetaldehyde level at 10, 20, and 40 minutes following alcohol consumption (see Figure 1) after receiving 28 days of Essential AD2. In addition, safety tests looking at liver function tests showed a decrease in Aspartate transaminase (AST) and Alanine transaminase (ALT) liver proteins from 27.3 to 15.2 and 20.9 to 13.2, respectively, over the 28 days. The treatment was well tolerated and no significant side effects were noted.